CN110407943B - 一种克百威农药的纳米抗体及其制备方法和应用 - Google Patents
一种克百威农药的纳米抗体及其制备方法和应用 Download PDFInfo
- Publication number
- CN110407943B CN110407943B CN201910341232.6A CN201910341232A CN110407943B CN 110407943 B CN110407943 B CN 110407943B CN 201910341232 A CN201910341232 A CN 201910341232A CN 110407943 B CN110407943 B CN 110407943B
- Authority
- CN
- China
- Prior art keywords
- nanobody
- carbofuran
- pesticide
- antibody
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000000575 pesticide Substances 0.000 title abstract description 25
- DUEPRVBVGDRKAG-UHFFFAOYSA-N carbofuran Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)C2 DUEPRVBVGDRKAG-UHFFFAOYSA-N 0.000 title description 54
- 238000001514 detection method Methods 0.000 claims abstract description 30
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 239000000427 antigen Substances 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 22
- 238000002965 ELISA Methods 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 15
- 239000011248 coating agent Substances 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- 102000014914 Carrier Proteins Human genes 0.000 claims description 7
- 108010078791 Carrier Proteins Proteins 0.000 claims description 7
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 5
- 230000008878 coupling Effects 0.000 claims description 5
- 238000010168 coupling process Methods 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 4
- JLQUFIHWVLZVTJ-UHFFFAOYSA-N carbosulfan Chemical compound CCCCN(CCCC)SN(C)C(=O)OC1=CC=CC2=C1OC(C)(C)C2 JLQUFIHWVLZVTJ-UHFFFAOYSA-N 0.000 claims description 3
- XSSYCIGJYCVRRK-RQJHMYQMSA-N (-)-carbovir Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1C[C@H](CO)C=C1 XSSYCIGJYCVRRK-RQJHMYQMSA-N 0.000 claims 2
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 7
- 238000011161 development Methods 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 239000000447 pesticide residue Substances 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 3
- 239000002773 nucleotide Substances 0.000 abstract description 3
- 125000003729 nucleotide group Chemical group 0.000 abstract description 3
- 239000002243 precursor Substances 0.000 abstract description 2
- 238000002708 random mutagenesis Methods 0.000 abstract description 2
- 238000002741 site-directed mutagenesis Methods 0.000 abstract description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 230000027455 binding Effects 0.000 description 15
- 238000005406 washing Methods 0.000 description 15
- 239000012634 fragment Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000001035 drying Methods 0.000 description 11
- 230000031700 light absorption Effects 0.000 description 8
- 239000011148 porous material Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000282828 Camelus bactrianus Species 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 230000000895 acaricidal effect Effects 0.000 description 2
- 239000000642 acaricide Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002917 insecticide Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- RHSUJRQZTQNSLL-UHFFFAOYSA-N 3-Hydroxy-carbofuran Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)C2O RHSUJRQZTQNSLL-UHFFFAOYSA-N 0.000 description 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GWFSQQNGMPGBEF-GHCJXIJMSA-N Ala-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N GWFSQQNGMPGBEF-GHCJXIJMSA-N 0.000 description 1
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 description 1
- SMCGQGDVTPFXKB-XPUUQOCRSA-N Ala-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N SMCGQGDVTPFXKB-XPUUQOCRSA-N 0.000 description 1
- AJBVYEYZVYPFCF-CIUDSAMLSA-N Ala-Lys-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O AJBVYEYZVYPFCF-CIUDSAMLSA-N 0.000 description 1
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 1
- PBSOQGZLPFVXPU-YUMQZZPRSA-N Arg-Glu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PBSOQGZLPFVXPU-YUMQZZPRSA-N 0.000 description 1
- JOADBFCFJGNIKF-GUBZILKMSA-N Arg-Met-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O JOADBFCFJGNIKF-GUBZILKMSA-N 0.000 description 1
- GSUFZRURORXYTM-STQMWFEESA-N Arg-Phe-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 GSUFZRURORXYTM-STQMWFEESA-N 0.000 description 1
- PFOYSEIHFVKHNF-FXQIFTODSA-N Asn-Ala-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PFOYSEIHFVKHNF-FXQIFTODSA-N 0.000 description 1
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 1
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 1
- 206010008428 Chemical poisoning Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- MSHXWFKYXJTLEZ-CIUDSAMLSA-N Gln-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MSHXWFKYXJTLEZ-CIUDSAMLSA-N 0.000 description 1
- WLRYGVYQFXRJDA-DCAQKATOSA-N Gln-Pro-Pro Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 WLRYGVYQFXRJDA-DCAQKATOSA-N 0.000 description 1
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 1
- KRRMJKMGWWXWDW-STQMWFEESA-N Gly-Arg-Phe Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KRRMJKMGWWXWDW-STQMWFEESA-N 0.000 description 1
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
- FHQRLHFYVZAQHU-IUCAKERBSA-N Gly-Lys-Gln Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O FHQRLHFYVZAQHU-IUCAKERBSA-N 0.000 description 1
- SYOJVRNQCXYEOV-XVKPBYJWSA-N Gly-Val-Glu Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SYOJVRNQCXYEOV-XVKPBYJWSA-N 0.000 description 1
- AFMOTCMSEBITOE-YEPSODPASA-N Gly-Val-Thr Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O AFMOTCMSEBITOE-YEPSODPASA-N 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- PMMMQRVUMVURGJ-XUXIUFHCSA-N Ile-Leu-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O PMMMQRVUMVURGJ-XUXIUFHCSA-N 0.000 description 1
- DTPGSUQHUMELQB-GVARAGBVSA-N Ile-Tyr-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=C(O)C=C1 DTPGSUQHUMELQB-GVARAGBVSA-N 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- QIJVAFLRMVBHMU-KKUMJFAQSA-N Lys-Asp-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QIJVAFLRMVBHMU-KKUMJFAQSA-N 0.000 description 1
- 231100000703 Maximum Residue Limit Toxicity 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- RIYZXJVARWJLKS-KKUMJFAQSA-N Phe-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 RIYZXJVARWJLKS-KKUMJFAQSA-N 0.000 description 1
- ILMLVTGTUJPQFP-FXQIFTODSA-N Pro-Asp-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ILMLVTGTUJPQFP-FXQIFTODSA-N 0.000 description 1
- QMABBZHZMDXHKU-FKBYEOEOSA-N Pro-Tyr-Trp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O QMABBZHZMDXHKU-FKBYEOEOSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- OLIJLNWFEQEFDM-SRVKXCTJSA-N Ser-Asp-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OLIJLNWFEQEFDM-SRVKXCTJSA-N 0.000 description 1
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 1
- NLOAIFSWUUFQFR-CIUDSAMLSA-N Ser-Leu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O NLOAIFSWUUFQFR-CIUDSAMLSA-N 0.000 description 1
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 1
- LLSLRQOEAFCZLW-NRPADANISA-N Ser-Val-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LLSLRQOEAFCZLW-NRPADANISA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- UBDDORVPVLEECX-FJXKBIBVSA-N Thr-Gly-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O UBDDORVPVLEECX-FJXKBIBVSA-N 0.000 description 1
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 1
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 1
- WTMPKZWHRCMMMT-KZVJFYERSA-N Thr-Pro-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WTMPKZWHRCMMMT-KZVJFYERSA-N 0.000 description 1
- SLOYNOMYOAOUCX-BVSLBCMMSA-N Trp-Phe-Arg Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SLOYNOMYOAOUCX-BVSLBCMMSA-N 0.000 description 1
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 1
- UUJHRSTVQCFDPA-UFYCRDLUSA-N Tyr-Tyr-Val Chemical compound C([C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 UUJHRSTVQCFDPA-UFYCRDLUSA-N 0.000 description 1
- YODDULVCGFQRFZ-ZKWXMUAHSA-N Val-Asp-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O YODDULVCGFQRFZ-ZKWXMUAHSA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 1
- 108010070783 alanyltyrosine Proteins 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- FYZBOYWSHKHDMT-UHFFFAOYSA-N benfuracarb Chemical compound CCOC(=O)CCN(C(C)C)SN(C)C(=O)OC1=CC=CC2=C1OC(C)(C)C2 FYZBOYWSHKHDMT-UHFFFAOYSA-N 0.000 description 1
- 239000000152 carbamate pesticide Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- DIRFUJHNVNOBMY-UHFFFAOYSA-N fenobucarb Chemical compound CCC(C)C1=CC=CC=C1OC(=O)NC DIRFUJHNVNOBMY-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QBSJMKIUCUGGNG-UHFFFAOYSA-N isoprocarb Chemical compound CNC(=O)OC1=CC=CC=C1C(C)C QBSJMKIUCUGGNG-UHFFFAOYSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000005645 nematicide Substances 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000361 pesticidal effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 108010074082 phenylalanyl-alanyl-lysine Proteins 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种克百威农药的纳米抗体及其制备方法和应用,该纳米抗体,其氨基酸序列如SEQ ID NO.1所示;编码其的基因,其核苷酸序列如SEQ ID NO.2所示。本发明得到一种针对克百威农药的纳米抗体,该纳米抗体能够检测克百威农药,且检测结果准确、效果好、稳定性好,在高温和有机溶剂的条件下还有很好的检测效果。该抗体不仅可以广泛的应用于农产品中克百威农药残留的检测;还可以作为前体,通过随机或定点突变技术进行改造,能够获得性质(亲和性、特异性、稳定性等)更好的突变体,用来发展进一步用于食品、医药、农业等领域,有很大的应用推广价值。
Description
技术领域
本发明涉及生物技术领域,更具体地,涉及一种克百威农药的纳米抗体及其制备方法和应用。
背景技术
氨基甲酸酯类化合物在农药上用作杀虫剂、杀螨剂、除草剂和杀菌剂,已形成农药的一大类别,品种多、药效好、低毒。氨基甲酸酯类农药是农药急性中毒的主要原因,也是时下蔬菜中农药残留的重点检测品种。
克百威商品名呋喃丹,是氨基甲酸酯类广谱内吸杀虫杀螨杀线虫剂,可用于多种作物防治土壤内及地面上的300多种害虫和线虫。并有缩短作物生长期、促进作物生长发育从而有效提高作物产量的作用。广泛应用于蔬菜、水果和粮食作物等的害虫防治中。但是,克百威对人和动物有很高的毒性,并且不易降解,容易造成环境污染。我国已规定食品中克百威的最大残留限量,但违规使用现象仍然较多,因此加强对克百威农药残留的检测十分必要。
目前,克百威残留分析一般使用气相色谱法(简称GC)、高效液相色谱法(简称HPLC)及色谱质谱联用技术,这些方法灵敏、准确,可以同时测定多种药物,但样品前处理复杂、繁琐费时,且需要昂贵的仪器设备和专业的操作人员,检测成本高,难以满足样品现场、批量、快速检测的需要。因此,开发一种简单快速、适用于农药残留现场监控的分析方法具有重要意义。而基于抗体建立的免疫分析方法,虽然具有快速、灵敏、高通量的优势,但是在极端条件下抗体往往稳定性差,容易失活。
因此目前缺乏一种稳定性好的克百威抗体。
发明内容
本发明的目的是为了克服现有技术的不足,提供一种克百威农药的纳米抗体及其制备方法和应用。
本发明的第一个目的是提供一种特异性识别克百威的纳米抗体。
本发明的第二个目的是提供一种编码特异性识别克百威纳米抗体的基因。
本发明的第三个目的是提供一种重组载体。
本发明的第四个目的是提供一种重组细胞。
本发明的第五个目的是提供所述纳米抗体、所述基因、所述重组载体、或所述重组细胞中的一种或几种在检测克百威或制备克百威的检测试剂盒中的应用。
本发明的第六个目的是提供所述纳米抗体的制备方法。
本发明的第七个目的是提供一种克百威的检测方法。
本发明的第八个目的是提供一种检测克百威的试剂盒。
为了实现上述目的,本发明是通过以下技术方案予以实现的:
纳米抗体的稳定性好、亲和力较高,克服了小分子功能抗体的缺点,同时又具有分子质量小、免疫原性弱、组织穿透力强等单克隆抗体、多克隆抗体不具备的优点。本发明通过噬菌体展示技术,从驼源免疫单域重链抗体库中筛选出能与靶分子(克百威完全抗原)特异性结合的纳米抗体,建立了一种快速、灵敏且稳定的检测蔬菜、茶叶中克百威残留的方法。
因此本发明要求保护以下内容:
一种特异性识别克百威的纳米抗体,其氨基酸序列如SEQ ID NO.1所示。
编码特异性识别克百威纳米抗体的基因,其核苷酸序列如SEQ ID NO.2所示。
一个重组载体,为连接有所述基因的载体。
优选地,所述载体为表达载体。
优选地,所述表达载体为pComb3xss。
一个重组细胞,携带有所述重组载体的细胞,或能够表达所述纳米抗体的细胞。
优选地,所述细胞为大肠杆菌BL21(DE3)。
所述纳米抗体、所述基因、所述重组载体、或所述重组细胞中的一种或几种在检测克百威或制备克百威的检测试剂盒中的应用。
所述纳米抗体的制备方法,包括以下步骤:
S1.将所述纳米抗体的编码基因连接到表达载体上,获得重组载体;
S2.将重组载体转入受体细胞,得到重组细胞;
S3.培养重组细胞,诱导表达纳米抗体;
S4.分离纯化得到纳米抗体。
优选地,步骤S3中,将重组细胞培养至对数期OD600值为0.6~0.8,诱导表达纳米抗体。
优选地,步骤S3中,使用0.1~1mM的IPTG,28~37℃诱导表达12~16h。
更优选地,步骤S3中,使用1mM的IPTG,37℃诱导表达12h。
优选地,步骤S4中,通过蔗糖渗透压法提取周质腔蛋白,经一步Ni柱纯化后回收周质腔中的可溶性纳米抗体。
一种克百威的检测方法,利用所述纳米抗体。
优选地,基于间接ELISA方法进行检测,用式(I)所述克百威半抗原与载体蛋白偶联得到的克百威完全抗原做包被原,用所述纳米抗体作为检测抗体,
优选地,所述载体蛋白为卵清白蛋白。
更优选地,所述检测方法包括以下步骤:包被原包被酶标版;加入克百威标准品或待测样品,再加入检测抗体;加入酶标记的二抗,孵育;加入显色液,孵育;加入终止液并测定;以克百威标准品浓度的log10值为横坐标,以各克百威标准品浓度的吸光值与零标准孔吸光值的比值为纵坐标,建立标准曲线,进而根据待测样品的吸光值来计算待测样品中的克百威药的含量。
进一步更优选地,用式(I)所述克百威半抗原与卵清白蛋白偶联得到的克百威完全抗原做包被原,稀释至工作浓度1μg/mL,加入酶标板,每孔100μL,37℃孵育过夜;洗板机洗板2次,甩干孔内液体,加入120μL的封闭液,37℃孵育2h,甩干孔内液体,倒置,37℃烘干1h;每孔加入50μL克百威标准品或待测样品,再加入50μL的所述纳米抗体,37℃孵育1h,洗板机洗板5次,甩干孔内液体;每孔加入100μL抗HA-HRP抗体(20000倍稀释),37℃孵育40min,洗板机洗板5次,甩干孔内液体;每孔加入100μL的TMB显色液,37℃孵育10min;再加入50μL的10%H2SO4终止显色反应;酶标仪测定A450nm吸光值;以克百威药物浓度的log10值为横坐标,吸光值比值B/B0为纵坐标,用Origin9.0的四参数拟合模块拟合标准曲线。
一种检测克百威的试剂盒,含有所述纳米抗体。
优选地,基于间接ELISA方法进行检测,还含有式(I)所述克百威半抗原与载体蛋白偶联得到的克百威完全抗原做包被原,用所述纳米抗体作为检测抗体,
优选地,所述载体蛋白为卵清白蛋白。
优选地,还含有酶标记的二抗、显色液和终止液。
与现有技术相比,本发明具有如下有益效果:
本发明得到一种针对克百威农药的纳米抗体,该纳米抗体能够检测克百威农药,且检测结果准确、效果好、稳定性好,在高温和有机溶剂的条件下还有很好的检测效果。该抗体不仅可以广泛的应用于农产品中克百威农药残留的检测;还可以作为前体,通过随机或定点突变技术进行改造,能够获得性质(亲和性、特异性、稳定性等)更好的突变体,用来发展进一步用于食品、医药、农业等领域,有很大的应用推广价值。
附图说明
图1为噬菌体单克隆间接竞争ELISA的检测结果。
图2为纳米抗体检测克百威农药标准曲线。
图3为纳米抗体在高温下5min的结合能力。
图4为在95℃下纳米抗体的结合活性。
图5为甲醇作为稀释液抗体与抗原的结合能力。
图6为乙腈作为稀释液抗体与抗原的结合能力。
具体实施方式
下面结合说明书附图和具体实施例对本发明作出进一步地详细阐述,所述实施例只用于解释本发明,并非用于限定本发明的范围。下述实施例中所使用的试验方法如无特殊说明,均为常规方法;所使用的材料、试剂等,如无特殊说明,为可从商业途径得到的试剂和材料。
实施例1抗克百威农药纳米抗体免疫文库的构建
一、实验方法
1、完全抗原BFNB-OVA和BFNB-KLH的制备
把克百威农药半抗原BFNB与卵清白蛋白OVA(albumin)和匙孔血蓝蛋白KLH(keyhole limpet heocyanin)通过偶联制备完全抗原BFNB-OVA和BFNB-KLH。
所述克百威农药半抗原BFNB的化学式为:
2、免疫双峰驼
取500μg的BFNB-KLH与等量体积的弗氏完全佐剂乳化,对双峰驼颈部皮下进行多点免疫注射。每隔2周加强免疫一次,每次500μg的BFNB-KLH和等量体积的弗氏不完全佐剂乳化后进行免疫,每次免疫一周后静脉采血。采用间接竞争ELISA方法测定血清效价。
3、RNA的提取和cDNA的合成
取血清抑制最好的血液样品进行淋巴细胞分离以及RNA的提取。RNA的提取依据Invitrogen公司的Trizol试剂方法进行。以RNA为模板,参照TAKARA公司第一链反转录试剂盒说明书进行cDNA第一链的合成。
4、纳米抗体基因片段的获得
利用Taq Mix DNA聚合酶,经PCR技术扩增获得骆驼重链抗体的可变区编码基因(引物如下表1)。
表1扩增VHH基因的引物序列:
将上一步获得的cDNA第一链分别进行一步法PCR和两步法PCR
(1)一步法PCR采用引物P1、P2和引物P1、P3分别扩增目的片段,反应条件为,94℃,5min,94℃,30s,61℃,30s,72℃,1min,30个循环,72℃延伸10min。PCR产物分别经琼脂糖凝胶电泳,回收500bp左右的片段,通过DNA切胶回收试剂盒回收目的片段,合并,得到纳米抗体基因片段,定量并置于-20℃保存备用;
(2)两步法PCR扩增第一步PCR采用引物Q1和Q2扩增,反应条件为,94℃,5min,94℃,30s,55℃,30s,72℃,1min,30个循环,72℃延伸10min。
把第一步PCR产物经琼脂糖凝胶电泳,回收500bp左右的片段,通过DNA切胶回收试剂盒回收目的片段。以回收的目的片段为模板,利用第二步引物Q3和Q4进行扩增,PCR反应条件同第一步。通过进一步切胶回收得到纳米抗体基因片段,定量并置于-20℃保存备用。
5、纳米抗体基因库的制备
将噬菌粒载体pComb3xss及上一步获得的两种纳米抗体基因片段进行sfiI双酶切,通过切胶回收和PCR纯化回收获得pComb3xss和两种纳米抗体基因片段。然后在16℃下,以pComb3xss和目的片段1:3的摩尔比混合,利用T4连接酶过夜连接反应。
上述连接产物经PCR纯化试剂盒进行沉淀回收,溶于35μl的无菌水。将一步法和两步法连接产物1:1混合,分13次电转化入感受态细胞ER2738中,转化菌液在200rpm,37℃摇床培养1小时复苏生长。梯度稀释转化菌液,涂布含氨苄青霉素和四环素的LB培养板,37℃过夜培养。次日,随机挑取涂布平板的单克隆,送公司测序,鉴定抗体库的多样性。库容依据克隆数目和多样性来计算。
用培养基将细胞刮洗下来,加入终浓度20%的无菌甘油,-80℃保存,即为克百威农药纳米抗体基因库。
6、纳米抗体噬菌体库的制备
取冻存的纳米抗体库1mL接种至200mL的LB(Amp,Tet)培养基,37℃,250rpm振荡培养至对数期(OD600=0.6~0.8)。加入1mL辅助噬菌体(1×1012pfu/mL),37℃静置培养30min,250rpm震荡培养2h,然后加卡那霉素(helper phage抗性)到70μg/mL,250rpm震荡培养过夜。将培养液4℃,12000rpm离心20min,上清液转移至新的离心瓶,加入50mL 5xPEG/NaCl混匀,冰上孵育4h。4℃,12000rpm离心15min,弃上清,加入1mL TBS重悬噬菌体沉淀,0.22μm滤膜过滤,加20%灭菌甘油,-20℃保存,即为纳米抗体噬菌体库。
实施例2抗克百威农药纳米抗体的筛选与鉴定
一、实验方法
1、以BFNB-OVA为包被抗原,酶标板每孔各100μl,37℃水浴孵育过夜。包被浓度梯度为10,5,1,0.2μg/ml。12h后,PBST洗板2次,10和1μg/ml的孔加入120μl的1%BSA,5和0.2μg/ml的孔加入120μl的1%鱼胶原蛋白,封闭3h,37℃,烘干待用。
2、取100μl噬菌体库(约1011pfu),分别加入2%的BSA、OVA和KLH载体蛋白,37℃孵育1h,除去非特异性吸附载体带白的抗体。然后转移至包被抗原孔内,室温震荡1小时,吸出未结合的噬菌体,用PBST洗板5次,10次,15次,15次。以100μl洗脱液(2,1,0.5,0.1μg/ml克百威)洗脱吸附于板孔内的噬菌体抗体。取出10μl用于滴度的测定,其余洗脱产物经辅助噬菌体救援扩增后用于下一轮的淘选。共进行4轮淘筛(见表2)。随机挑取第三轮和四轮的噬菌体单克隆进行间接竞争ELISA。
表2淘筛策略表:
Recovery=output phage/input phage
Enrichment=after round/previous round
二、实验结果
第三轮和四轮的噬菌体单克隆进行间接竞争ELISA结果如图1所示,获得九种不同序列的纳米抗体:Nb309(393bp)、Nb316(393bp)、Nb328(375bp)、Nb391(393bp)、Nb393(372bp)、Nb415(372bp)、Nb438(372bp)、Nb480(384bp)、Nb489(366bp)抗体。经过筛选,Nb316的抑制效果最好,其氨基酸序列如SEQ ID NO.1所示;核苷酸序列如SEQ ID NO.2所示。
实施例3克百威农药纳米抗体的制备与间接竞争ELISA方法的建立
一、实验方法
1、将Nb316-pComb3xss质粒通过提取试剂盒抽提,然后通过化学转化方法导入感受态大肠杆菌BL21(DE3)。取单克隆进行PCR鉴定和测序,确定插入片段为目的片段。将含有纳米抗体目的片段的BL21(DE3)菌落培养至对数期OD600值为0.6~0.8,加入终浓度为1mM的IPTG,37℃诱导表达12h。次日,离心得菌体。然后通过蔗糖渗透压法提取周质腔蛋白,经一步Ni柱纯化后回收周质腔中的可溶性纳米抗体Nb316。
2、以BFNB-OVA为包被原,稀释至工作浓度1μg/mL,加入96孔酶标板,每孔100μL,37℃孵育过夜。次日,洗板机洗板2次,甩干孔内液体,加入120μL的封闭液,37℃孵育2h,甩干孔内液体,倒置于37℃烘箱烘1h后取出备用。每孔加入50μL梯度稀释的药物和50μL的纳米抗体,每个浓度做三个重复。37℃孵育1h,洗板机洗板5次,甩干孔内液体,每孔加入100μL抗HA-HRP抗体(20000倍稀释),37℃孵育40min,洗板机洗板5次,甩干孔内液体。每孔加入100μL的TMB显色液,37℃孵育10min,再加入50μL的10%H2SO4终止显色反应,酶标仪测定A450nm吸光值。以克百威药物浓度为横坐标,吸光值比值B/B0为纵坐标,用Origin9.0的四参数拟合模块拟合标准曲线。
二、实验结果
结果显示,基于纳米抗体Nb2检测克百威的间接竞争ELISA标准曲线(如图2),IC50为7.27±0.88ng/ml,线性范围为1.44~30.40ng/ml。
实施例4间接竞争ELISA检测多种氨基甲酸酯类农药
一、实验方法
1、以BFNB-OVA为包被原,Nb316为检测抗体,采用间接竞争ELISA方法对氨基甲酸酯类农药的特异性及灵敏度进行评价。
具体步骤如下:每孔加入50μL梯度稀释的药物和50μL的纳米抗体,每个浓度做三个重复。37℃孵育1h,洗板机洗板5次,甩干孔内液体,每孔加入100μL抗HA-HRP抗体(20000倍稀释),37℃孵育40min,洗板机洗板5次,甩干孔内液体。每孔加入100μL的TMB显色液,37℃孵育10min,再加入50μL的10%H2SO4终止显色反应,酶标仪测定A450nm吸光值。以克百威药物浓度为横坐标,吸光值比值B/B0为纵坐标,用Origin9.0的四参数拟合模块拟合标准曲线,得出各自的IC50值。用下式计算各药物与抗克百威纳米抗体的交叉反应率:
CR(%)=100×IC50(克百威)/IC50(克百威类似物)。
2、结果显示,纳米抗体Nb316与丙硫克百威、仲丁威、丁硫克百威、3-羟基克百威和异丙威的交叉反应率分别为5.05%、3.52%、2.56%、1.97%和0.35%,与其余7种农药交叉反应率低于0.1%(见表3)。
表3纳米抗体Nb316的ic-ELISA方法检测农药的灵敏度和特异性:
实施例5克百威农药纳米抗体的热稳定性分析
一、实验方法
1、将纳米抗体Nb316稀释至工作浓度,分成七等份,分别置于20、35、50、65、80和95℃水浴锅中加热5min。待抗体恢复至室温,采用ic-ELISA测定抗体与抗原的结合能力,未加热的抗体与抗原结合的能力作为100%,评价纳米抗体不同温度下的稳定性。
2、将纳米抗体Nb316稀释至工作浓度,分成7等份,置于95℃水浴锅中,分别加热10、20、30、40、50、60min。待抗体恢复至室温,采用实施例4的ic-ELISA测定抗体与抗原的结合能力,未加热的抗体与抗原结合的能力作为100%,评价纳米抗体在高温下随着时间的增加稳定性的变化。
二、实验结果
结果显示:纳米抗体Nb 316在95℃下5min仍能保持100%以上的活性,因此,纳米抗体在高温下仍具有较强的结合能力(图3)。在95℃下,0min到60min,纳米抗体始终保持在约100%的结合活性(图4)。
实施例6克百威农药纳米抗体的有机溶剂耐受性分析
一、实验方法
用不同浓度(10%,20%,40%,60%和80%)的甲醇和乙腈作为稀释液,将纳米抗体Nb316稀释至同一工作浓度,采用实施例4的ic-ELISA测定抗体与抗原的结合能力,未加有机溶剂稀释液稀释的抗体与抗原结合能力作为100%,评价纳米抗体对不同有机溶剂、同一有机溶剂不同浓度时的耐受能力。
二、实验结果
结果显示:甲醇浓度为25%时,纳米抗体Nb316仍可保持约100%的结合活性,甲醇浓度为50%时,结合活性仍有50%(图5)。而在乙腈环境下,乙腈浓度低于20%时纳米抗体的结合活性不会降低,30%时纳米抗体仍具有50%的结合活性(图6)。因此,纳米抗体具有优异的有机溶剂耐受性,在实际样品检测的前处理过程中,不会受到残留有机溶剂的影响。
序列表
<110> 华南农业大学
<120> 一种克百威农药的纳米抗体及其制备方法和应用
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 131
<212> PRT
<213> 未知(Unknown)
<400> 1
Glu Val Gln Leu Val Asp Ser Gly Gly Gly Ser Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser Thr Pro Ala Tyr Tyr Val Tyr
20 25 30
Arg Met Ala Trp Phe Arg Gln Pro Pro Gly Lys Gln Arg Glu Gly Val
35 40 45
Ala Gly Val Asp Arg Val Gly Val Thr Ile Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Lys Asp Phe Ala Lys Asn Ser Leu Asp Leu
65 70 75 80
Gln Met Asn Ser Leu Gly Pro Asp Asp Thr Gly Met Tyr Tyr Cys Ala
85 90 95
Ala Asp Ile Arg Phe Gly Gly Val Glu Asn Ala Arg Ile Leu Pro Ser
100 105 110
Phe Asp Leu Ser Asp Phe Pro Tyr Trp Gly Gln Gly Thr Leu Val Thr
115 120 125
Val Ser Ser
130
<210> 2
<211> 393
<212> DNA
<213> 未知(Unknown)
<400> 2
tgaggagacg gtgaccaggg tcccctggcc ccagtaagga aagtcagaca aatcaaagga 60
ggggaggatt cgggcatttt cgacaccgcc gaatcgaata tcggccgcac agtagtacat 120
gccagtgtcg tcaggtccca agctgttcat ttgtagatcc agactgttct tggcgaagtc 180
tttggagatg gtgaatcggc ccttcacgga gtctgcgtag attgtaaccc ccactctatc 240
aacacctgcg accccctcgc gctgcttccc tggaggctgg cggaaccagg ccatgcgata 300
gacatagtag gcgggcgtgg agactgcaca ggagagtctc agagaccctc cagcctgcac 360
cgagcctccc ccagaatcca ccagctgcac ctc 393
Claims (10)
1.一种特异性识别克百威的纳米抗体,其特征在于,其氨基酸序列如SEQ ID NO.1所示。
2.一种编码权利要求1所述特异性识别克百威纳米抗体的基因。
3.一种重组载体,其特征在于,为连接有权利要求2所述基因的载体。
4.一种重组细胞,其特征在于,携带有权利要求3所述重组载体的细胞,或能够表达权利要求1所述纳米抗体的细胞。
5.权利要求1所述纳米抗体、权利要求2所述基因、权利要求3所述重组载体、或权利要求4所述重组细胞中的一种或几种在制备克百威的检测试剂盒中的应用。
6.权利要求1所述纳米抗体的制备方法,其特征在于,包括以下步骤:
S1.将权利要求2所述纳米抗体的编码基因连接到表达载体上,获得重组载体;
S2.将重组载体转入受体细胞,得到重组细胞;
S3.培养重组细胞,诱导表达纳米抗体;
S4.分离纯化得到纳米抗体。
7.一种非治疗或诊断目的的克百威检测方法,其特征在于,利用权利要求1所述的纳米抗体。
9.一种检测克百威的试剂盒,其特征在于,含有权利要求1所述纳米抗体。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910341232.6A CN110407943B (zh) | 2019-04-25 | 2019-04-25 | 一种克百威农药的纳米抗体及其制备方法和应用 |
PCT/CN2019/122580 WO2020215727A1 (zh) | 2019-04-25 | 2019-12-03 | 一种克百威农药的纳米抗体及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910341232.6A CN110407943B (zh) | 2019-04-25 | 2019-04-25 | 一种克百威农药的纳米抗体及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110407943A CN110407943A (zh) | 2019-11-05 |
CN110407943B true CN110407943B (zh) | 2021-03-30 |
Family
ID=68357679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910341232.6A Active CN110407943B (zh) | 2019-04-25 | 2019-04-25 | 一种克百威农药的纳米抗体及其制备方法和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110407943B (zh) |
WO (1) | WO2020215727A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110407943B (zh) * | 2019-04-25 | 2021-03-30 | 华南农业大学 | 一种克百威农药的纳米抗体及其制备方法和应用 |
CN114409795B (zh) * | 2021-12-24 | 2023-05-12 | 华南农业大学 | 一种检测二嗪农的纳米抗体及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106771222A (zh) * | 2016-12-16 | 2017-05-31 | 中国农业科学院农业质量标准与检测技术研究所 | 一种克百威分析测定试剂盒及其应用 |
CN108659129A (zh) * | 2018-05-17 | 2018-10-16 | 新疆大学 | 一种抗gpc3蛋白的纳米抗体及其制备方法和应用 |
CN109053884A (zh) * | 2015-11-02 | 2018-12-21 | 东南大学 | Wasabi蛋白纳米抗体及其编码序列与应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5283066A (en) * | 1992-02-19 | 1994-02-01 | Development Center For Biotechnology | Method of stimulating an immune response by using a hapten |
CN101008645B (zh) * | 2006-09-30 | 2012-05-30 | 华南农业大学 | 一种检测克百威的酶联免疫试剂盒 |
PL3049439T3 (pl) * | 2013-09-26 | 2020-07-13 | Ablynx N.V. | Bispecyficzne nanociała |
CN105137009B (zh) * | 2015-09-18 | 2016-08-17 | 北京勤邦生物技术有限公司 | 检测克百威的酶联免疫试剂盒及其应用 |
CN106367396B (zh) * | 2016-10-14 | 2019-07-16 | 江南大学 | 一株克百威单克隆抗体杂交瘤细胞株yh1及其应用 |
CN108794632B (zh) * | 2017-12-28 | 2021-07-09 | 华南农业大学 | 一种广谱特异性识别二乙氧基有机磷农药的纳米抗体及酶联免疫分析方法 |
CN108218747A (zh) * | 2017-12-29 | 2018-06-29 | 华南农业大学 | 氟苯尼考半抗原、人工抗原与单克隆抗体及其酶联免疫检测方法 |
CN110407943B (zh) * | 2019-04-25 | 2021-03-30 | 华南农业大学 | 一种克百威农药的纳米抗体及其制备方法和应用 |
-
2019
- 2019-04-25 CN CN201910341232.6A patent/CN110407943B/zh active Active
- 2019-12-03 WO PCT/CN2019/122580 patent/WO2020215727A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109053884A (zh) * | 2015-11-02 | 2018-12-21 | 东南大学 | Wasabi蛋白纳米抗体及其编码序列与应用 |
CN106771222A (zh) * | 2016-12-16 | 2017-05-31 | 中国农业科学院农业质量标准与检测技术研究所 | 一种克百威分析测定试剂盒及其应用 |
CN108659129A (zh) * | 2018-05-17 | 2018-10-16 | 新疆大学 | 一种抗gpc3蛋白的纳米抗体及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2020215727A1 (zh) | 2020-10-29 |
CN110407943A (zh) | 2019-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108794632B (zh) | 一种广谱特异性识别二乙氧基有机磷农药的纳米抗体及酶联免疫分析方法 | |
CN103866401B (zh) | 一种黄曲霉毒素纳米抗体基因库、构建方法、用途及黄曲霉毒素b1纳米抗体2014afb-g15 | |
CN106680484B (zh) | 分析甲萘威残留的elisa检测试剂盒及其应用 | |
US9128089B1 (en) | Aflatoxin M1 nanobody 2014AFM-G2 | |
Gong et al. | Specific determination of influenza H7N2 virus based on biotinylated single-domain antibody from a phage-displayed library | |
CN111303292B (zh) | 一种特异性识别百草枯的纳米抗体Nb2-37及其应用 | |
CN110407943B (zh) | 一种克百威农药的纳米抗体及其制备方法和应用 | |
CN109705215A (zh) | 一种具有高特异性识别黄曲霉毒素b1的纳米抗体2018afb-n11及其应用 | |
CN113388037B (zh) | 一种特异性识别杀螟硫磷纳米抗体的制备及其应用 | |
CN111234014B (zh) | 一种广谱识别藻毒素纳米抗体及酶联免疫分析方法 | |
CN112920277B (zh) | 分析溴氰虫酰胺和氯虫苯甲酰胺残留的vhh-elisa试剂盒及其应用 | |
CN113307877B (zh) | 一种同时识别杀螟硫磷及甲基对硫磷的纳米抗体制备及应用 | |
CN112457407B (zh) | 一种丙烯酰胺特异性纳米抗体的制备及其应用 | |
CN107543918B (zh) | 一步法检测甲萘威残留的elisa试剂盒及其应用 | |
CN111454171B (zh) | 一种百草枯半抗原ph-a、人工抗原、抗体及其制备方法和应用 | |
AU2020103284A4 (en) | Nanobody for carbofuran pesticide and preparation method and use thereof | |
CN110734497B (zh) | 一种直接识别异丙威的单链抗体及其制备方法和应用 | |
CN110684080B (zh) | 一种适用于噻虫嗪残留分析的scFv-ELISA试剂盒 | |
CN114702592B (zh) | 一种识别喹硫磷农药的纳米抗体及酶联免疫分析方法 | |
CN107817341B (zh) | 基于纳米抗体检测三唑磷残留的elisa试剂盒及其应用 | |
CN111499737B (zh) | 一种特异性检测藻毒素类物质的纳米抗体及酶联免疫分析方法 | |
CN108218992B (zh) | 一种直接识别3-氨基-5-吗啉甲基-2-恶唑烷酮的单链抗体及其制备方法和应用 | |
CN107557358A (zh) | 基于纳米抗体检测氟虫腈残留的elisa试剂盒及其应用 | |
CN107417790B (zh) | 一种适用于三唑磷残留分析的vhh-elisa试剂盒 | |
CN114644712B (zh) | 一种检测腐霉利的方法及试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |